首页 | 本学科首页   官方微博 | 高级检索  
     


Novel developments in the treatment of acute bacterial skin and skin structure infections
Authors:Rupal K. Jaffa  Kelly E. Pillinger  Danya Roshdy  Jacqueline A. Isip
Affiliation:1. Department of Pharmacy, Carolinas Medical Center, Charlotte, NC, USA;2. Department of Pharmacy, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA
Abstract:
ABSTRACT

Introduction: Acute bacterial skin and skin structure infection (ABSSSI) represents a major burden for healthcare systems. The increased prevalence of Methicillin-resistant Staphylococcus aureus, combined with the limited availability of microbiologic data when treating ABSSSI, has led to a need for more convenient, less toxic anti-MRSA agents. Recent approvals have added several agents to the antibiotic armamentarium that provide an expanded spectrum of activity and ease of administration compared to older agents.

Areas covered: In this review, the authors discuss updated approaches to the management of ABSSSI. They also provide a review of recent FDA approved antibiotics and emerging investigational agents for treatment of ABSSSI.

Expert opinion: Several new antibiotic agents have received FDA approval through the revised guidance on ABSSSI clinical trials with advantages of activity against MRSA and ease of administration. In theory, this may translate to reducing the utilization of healthcare resources by allowing for earlier discharge and reducing the need for outpatient parenteral therapy. While the approval of new agents offers the opportunity to improve and simplify treatment of ABSSSI, it is more important now than ever to use these agents in a responsible manner.
Keywords:Acute bacterial skin and skin structure infections  antimicrobial stewardship  dalbavancin  delafloxacin  omadacycline  oritavancin  tedizolid
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号